Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Donald Notman Sells 11,119 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 11,119 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the sale, the insider now directly owns 193,444 shares in the company, valued at $1,510,797.64. The trade was a 5.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Donald Notman also recently made the following trade(s):

• On Friday, January 31st, Donald Notman sold 6,301 shares of Ocular Therapeutix stock. The shares were sold at an average price of $7.84, for a total value of $49,399.84.

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $7.82 on Wednesday. Ocular Therapeutix, Inc. has a 12-month low of $4.06 and a 12-month high of $11.77. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The stock has a 50-day moving average price of $8.61 and a 200-day moving average price of $9.02.

Analyst Upgrades and Downgrades

Several research analysts have commented on OCUL shares. Scotiabank initiated coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Ocular Therapeutix presently has a consensus rating of “Moderate Buy” and an average price target of $16.71.

Institutional Investors Weigh In On Ocular Therapeutix

Hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Ocular Therapeutix by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 1,015 shares during the last quarter. Essex Investment Management Co. LLC increased its stake in Ocular Therapeutix by 0.3% in the third quarter. Essex Investment Management Co. LLC now owns 443,677 shares of the biopharmaceutical company’s stock valued at $3,860,000 after acquiring an additional 1,168 shares during the last quarter. HighVista Strategies LLC raised its position in Ocular Therapeutix by 5.1% during the third quarter. HighVista Strategies LLC now owns 65,027 shares of the biopharmaceutical company’s stock valued at $566,000 after purchasing an additional 3,168 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Ocular Therapeutix by 11.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company’s stock worth $285,000 after purchasing an additional 3,347 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Ocular Therapeutix by 2.7% in the 4th quarter. Rhumbline Advisers now owns 213,601 shares of the biopharmaceutical company’s stock worth $1,824,000 after purchasing an additional 5,682 shares in the last quarter. 59.21% of the stock is currently owned by institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.